These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29517501)

  • 1. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome.
    Cook HT
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):165-170. PubMed ID: 29517501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].
    Yurova VA; Kozlovskaya NL; Bobrova LA; Kozlov LV; Andina SS; Demyanova KA
    Ter Arkh; 2023 Aug; 95(6):475-480. PubMed ID: 38158966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of complement in kidney disease.
    Willows J; Brown M; Sheerin NS
    Clin Med (Lond); 2020 Mar; 20(2):156-160. PubMed ID: 32188650
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zipfel PF; Wiech T; Stea ED; Skerka C
    J Am Soc Nephrol; 2020 Feb; 31(2):241-256. PubMed ID: 31980588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
    Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
    J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities.
    Antonucci L; Thurman JM; Vivarelli M
    Pediatr Nephrol; 2024 May; 39(5):1387-1404. PubMed ID: 37733095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on C3 Glomerulopathy.
    Wooden B; Nester CM; Bomback AS
    Adv Kidney Dis Health; 2024 May; 31(3):223-233. PubMed ID: 39004462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin and renin blockade have no role in complement activity.
    Zhang Y; Martin B; Spies MA; Roberts SM; Nott J; Goodfellow RX; Nelson AFM; Blain SJ; Redondo E; Nester CM; Smith RJH
    Kidney Int; 2024 Feb; 105(2):328-337. PubMed ID: 38008161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complement system in the pathogenesis and progression of kidney diseases: What doesn't kill you makes you older.
    Stea ED; D'Ettorre G; Mitrotti A; Gesualdo L
    Eur J Intern Med; 2024 Jun; 124():22-31. PubMed ID: 38461065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.
    Bartoli G; Dello Strologo A; Grandaliano G; Pesce F
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.
    Meuleman MS; Petitprez F; Pickering MC; Le Quintrec M; Artero MR; Duval A; Rabant M; Gilmore A; Boyer O; Hogan J; Servais A; Provot F; Gnemmi V; Eloudzeri M; Grunenwald A; Buob D; Boffa JJ; Moktefi A; Audard V; Goujon JM; Bridoux F; Thervet E; Karras A; Roumenina LT; Frémeaux Bacchi V; Duong Van Huyen JP; Chauvet S
    J Am Soc Nephrol; 2024 Aug; 35(8):1034-1044. PubMed ID: 38709564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Challenges and Emerging Pathogeneses of Selected Glomerulopathies.
    Andeen NK; Hou J
    Pediatr Dev Pathol; 2024 Apr; ():10935266241237656. PubMed ID: 38576387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement Dysregulation and Disease: Insights from Contemporary Genetics.
    Liszewski MK; Java A; Schramm EC; Atkinson JP
    Annu Rev Pathol; 2017 Jan; 12():25-52. PubMed ID: 27959629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 Glomerulopathy: Novel Treatment Paradigms.
    Tarragon Estebanez B; Bomback AS
    Kidney Int Rep; 2024 Mar; 9(3):569-579. PubMed ID: 38481517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.
    Ricklin D; Reis ES; Mastellos DC; Gros P; Lambris JD
    Immunol Rev; 2016 Nov; 274(1):33-58. PubMed ID: 27782325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases.
    Miwa T; Sato S; Golla M; Song WC
    Annu Rev Med; 2024 Jan; 75():189-204. PubMed ID: 37669567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital Ischemia as a Rare Manifestation of C3 Glomerulopathy Associated With Monoclonal Gammopathy.
    Baber A; Legendre P; Chauvet S; Karras A; Deshayes S; Huart A; Vignon M; Dessaix K; Hervier B; Legallicier B; Silva NM; Frémeaux-Bacchi V; Terrier B
    Kidney Int Rep; 2024 Mar; 9(3):712-716. PubMed ID: 38481513
    [No Abstract]   [Full Text] [Related]  

  • 18. A typical clinical manifestation of atypical underlying diagnosis: Answers.
    B N; Cj NA; Mk AM; I MI
    Pediatr Nephrol; 2023 Nov; 38(11):3615-3617. PubMed ID: 37160459
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Vivarelli M; Barratt J; Beck LH; Fakhouri F; Gale DP; Goicoechea de Jorge E; Mosca M; Noris M; Pickering MC; Susztak K; Thurman JM; Cheung M; King JM; Jadoul M; Winkelmayer WC; Smith RJH;
    Kidney Int; 2024 Sep; 106(3):369-391. PubMed ID: 38844295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren and the dual complement inhibition concept.
    Perez-Gomez MV; Ortiz A
    Clin Kidney J; 2020 Feb; 13(1):35-38. PubMed ID: 32083617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.